+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating zipalertinib, a new EGFR tyrosine kinase inhibitor TKI, compared to a placebo in people with early stage non-small cell lung cancer NSCLC who have uncommon EGFR mutations and have had their tumors completely surgically removed. The study focuses on participants with specific uncommon EGFR mutations, including exon 20 insertions and others in exons 18-21, aiming to understand the treatments impact on disease-free survival after surgery. Participants are randomly assigned to receive either zipalertinib or a matching placebo, both taken orally twice daily. Treatment continues until certain criteria for stopping are met. An independent committee will monitor safety during the study. The study plans to include about 360 participants and will last up to 5 years for measuring outcomes. Throughout the trial, participants will be closely monitored with brain imaging before starting treatment to ensure no brain metastases. Researchers will assess disease-free survival as their main outcome over up to 5 years, along with overall survival and quality of life measures. Safety will be evaluated through tracking adverse events, lab tests, vital signs, heart function via ECG and scans, and quality of life questionnaires. Participants will have regular visits for treatment and assessment over the study period.

Age: 18Years +All GendersPhase 3
253 locations
R

Actively Recruiting

Researchers are evaluating the effects of Nintedanib Solution for Inhalation AP02 on lung function and fibrosis in adults with idiopathic pulmonary fibrosis IPF. This phase 2 study aims to assess the safety, tolerability, and efficacy of AP02 by comparing two different doses to a placebo in participants 40 years or older with IPF who are either untreated or have stopped certain IPF medications for at least 3 months. Participants will be randomly assigned to one of three groups to receive either a low dose, high dose of AP02, or placebo solution via inhalation using a nebulizer twice daily for 12 weeks. The study includes a 16-week period during which participants will attend six office visits and receive one phone call for ongoing assessments and monitoring. Throughout the trial, lung function will be measured with breathing tests, and participants will complete health questionnaires. Researchers will monitor lung fibrosis through imaging scores and track disease progression over 12 weeks. Safety and health will be regularly checked by doctors during visits, ensuring careful observation of participants well-being during the study.

Age: 40Years +All GendersPhase 2
49 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are investigating the levels of bone breakdown markers RANKL, OPG and oxidative stress markers Nitrotyrosine, NQO1, along with inflammatory proteins IL-1, in saliva and peri-implant sulcular fluid PISF among people with peri-implantitis, periodontitis, and healthy subjects. The goal is to understand if these markers can help diagnose and track the early stages and progression of diseases affecting dental implants and surrounding tissues. Participants will be divided into four groups based on clinical and X-ray exams those with peri-implantitis, periodontitis, peri-implant health, and periodontal health. Saliva samples and fluid from around teeth and implants will be collected following specific protocols to measure the markers using specialized lab tests ELISA kits. The study includes detailed dental assessments such as probing depths and bleeding scores. During the study, participants will have clinical exams measuring plaque, gum inflammation, bleeding, and attachment loss around teeth or implants. Samples will be collected in the morning under controlled conditions to ensure accuracy. Researchers will analyze the levels of key proteins in these samples to evaluate their potential as diagnostic tools. The study will monitor these measures at the start of participation to compare across groups.

Age: 18Years - 65YearsAll Genders
1 location
G

Actively Recruiting

Researchers are conducting a Phase 23, multisite, randomized, open-label trial to study first-line treatments for non-small cell lung cancer NSCLC. This trial includes two substudies focusing on different NSCLC histological subtypes due to variations in standard chemotherapy choices. The study aims to evaluate the safety, effectiveness, and behavior of the investigational drug pumitamig combined with chemotherapy and compare it to pembrolizumab plus chemotherapy. Participants in each substudy first join a Phase 2 part where they receive one of two doses of pumitamig plus chemotherapy. In the Phase 3 part, they are randomized to receive either pumitamig plus chemotherapy or pembrolizumab plus chemotherapy. Additional participants in China will be enrolled in a Phase 2 arm to further evaluate a selected dose. Independent committees will review safety data and tumor scans throughout the study. Participants will be involved for up to 64 months, undergoing treatments through intravenous infusions. Their health will be monitored regularly to track side effects, tumor response, progression-free survival, overall survival, and quality of life through questionnaires and scans. Safety assessments include monitoring adverse events and treatment tolerance, with follow-up visits extending up to several years to assess long-term outcomes.

Age: 18Years +All GendersPhase 2Phase 3
366 locations